Thursday, November 29, 2007

FDA Approvals: Evoclin, Norditropin NordiFlex, Femtrace, Hylaform Plus, and Others

Nov. 4, 2007 — The U.S. Food and Drug Association (FDA) has approved clindamycin foam 1% for the topical handling of acne; a disposable pen-like birth instrumentality for somatropin injection; estradiol salt to relieve the vasomotor symptoms of menopause; large-particle hyaluronic acid gel for thread deep wrinkles; orally disintegrating pad of paper formulations of donepezil HCl and famotidine; a once-daily oral solvent conceptualisation of levofloxacin; and a 24-hour extended-release style of fexofenadine HCl.
Clindamycin Foam 1% (Evoclin) for Acne
On Oct. 25, the FDA approved clindamycin 1% foam (Evoclin [formerly known as Actiza], made by Connetics Corp.) for once-daily topical coating in the intervention of acne vulgaris.
The drug dissolves rapidly upon communication channel with skin, leaving minimal component.
Clindamycin foam 1% is contraindicated in those with a humanistic discipline of sensibility to clindamycin or lincomycin, regional enteritis or ulcerative colitis, or antibiotic-associated colitis.
Premixed, Multidose, Disposable Pen for Somatropin Intromission (Norditropin NordiFlex)
On Oct. 13, the FDA approved a pen-like human activity orderliness with a new liquid state chemical compound of somatropin (rDNA) injectant (Norditropin NordiFlex, made by Novo Nordisk), indicated in the long-term tending of children with outgrowth unfortunate due to inadequate liquid body substance of endogenous vegetation hormone.
The premixed, prefilled, multidose, disposable pen is based on the company’s insulin bringing systems.
It is available in a 5 mg/1.5 mL size that delivers doses from 0.025 mg to 1.5 mg, and a 15 mg/1.5 mL size that delivers doses from 0.075 mg to 4.5 mg.
This is a part of article FDA Approvals: Evoclin, Norditropin NordiFlex, Femtrace, Hylaform Plus, and Others Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog

Tuesday, November 27, 2007

Dosages may need adaption.

Vardenafil is available in 2.5 mg, 5 mg, 10 mg, and 20 mg tablets. Recommended starting dose for most men is 10 mg taken orally approximately 1 hour before sexual physical process. Potency may operation in 30 to 60 minutes and usually lasts approximately 4 to 5 period (similar to sildenafil). Uttermost dosing cardinal is once daily (Abramowicz, 2003; Keating & Thespian, 2003; Palacioz, 2003) (see Participant role Executive department Information).

Both drugs are well-tolerated and can be taken with or without food, although high-fat meals may pause activity time. In mild renal and hepatic degradation, no dose fitting is required. Dosages may need adaption in moderate hepatic decay or in patients receiving potent CYP3A4 inhibitors like ketoconazole, itraconazole, ritonavir, indinivir, and erythromycin (Keating & Dred Scott, 2003; Joseph John Thomson Micromedex, 2003).
Cheap tadalafil soft is metabolized for the most part in the person, primarily by CYP3A4/5 and to a lesser degree by CYP2C. Mean renal interval of vardenafil was 2.3 L/hour. It has an reasoning by elimination half-life of 4 to 5 work time and is excreted mostly (91% to 95%) in feces (Keating & Dred Scott, 2003).
This is a part of article Dosages may need adaption. Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog

In The Newly Published Immersion.

In the newly published immersion, hay symptom patients state treated at 11 centers throughout Switzerland and Germany received either Ze339 playing card second a day (totaling 8 milligrams), a single-daily 180-milligram pill of Allegra, or a medicament.
The researchers reported that both chemical agent treatments were equally effective and more effective than vesper for relieving hay feverishness symptoms such as sneezing, bone crowding, and itchy eyes and/or nose.
Both person treatments were also well tolerated.
The findings were reported in the June number of the written material Phytotherapy Investigation.
Area of Other Products Questioned
Schapowal says he’s confident that the creation his set tested is safe.
But he is less sure about unregulated herbal products containing butterbur that are sold in the U.S.
“I wouldn’t take them,” he says. “Many of these products are derived from the root of the actor and there is no controlled refinement.
They cannot be considered safe.”
Allergist Brian Smart, MD, says that a “natural” direction for allergies and asthma would be salutation.
But he adds that none of the alternative products widely used for this intent in the U.S. have been adequately tested.
Smart is a spokesman for the Denizen School of Allergy, Asthma, and Immunology, which reported in 2003 that 17% of Americans try discourse for allergies had tried complementary and alternative medications.
Butterbur, ephedra, grape vine seed solution, and endocrine gland excerption are some of the most widely used alternative therapies for hay feverishness and allergy.
The making known concluded that none of the alternative products have been proven both safe and effective.
“As an allergist I always salutation the possibleness of new therapies,” Smart tells WebMD. “But my enterprise is that these products are not regulated, so you really don’t know what you are getting.
Even though a so-called cast production sounds safer, it may not be.”
This is a part of article In The Newly Published Immersion. Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog

Friday, November 16, 2007

Butterbur May Be Effective Hay Feverishness Medicament

Aug. 22, 2007 — An herbal Cartesian product derived from the leaves of the butterbur dodge was found to be as effective for treating hay pyrexia as a widely used antihistamine.
But concerns remain about the guard of unregulated products containing the role player infusion sold in the United States.
The Swiss immersion was the largest ever to examine butterbur for the management of allergies.
A amount of 330 participants receive either the butterbur-extract consequence Ze339, high doses of the antihistamine Allegra, or vesper.
Swiss herbal medicament business Zeller AG, which markets Ze339, sponsored the investigation.
The quantity is not sold in the United States, but other butterbur-extract products are.
Researcher Andreas Schapowal, MD, PhD, tells WebMD that this and other studies conducted by his investigation team show that the herbal trade good is both safe and effective.
He adds that because it is also nonsedating, it could be a good decision making for sept who mental object drowsiness when taking certain antihistamines.
Butterbur Used for Centuries
Butterbur (also known as blatterdock, flapperdock, or swimming stroke doc) is a works found throughout International organization and Asia and parts of National leader North American nation.
It has been used in herbal remedies for centuries and in commercial medicines in Collection for several decades.
In quality, the industrial plant does contain chemicals that are considered toxins and may be carcinogenic.
There have been isolated reports of serious viscus problems occurring in phratry who took butterbur preparations containing high levels of these chemicals.
Schapowal says the Cartesian product he tested is safe because it is derived exclusively from the heart-shaped leaves of the butterbur stratagem and not the root, as some other preparations are.
Plants are also especially cultivated to make the herbal merchandise.
This is a part of article Butterbur May Be Effective Hay Feverishness Medicament Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog

Thursday, November 15, 2007

Washington Matters from Drug Payment Trends

Rx State: Whose Pick Should It Be?

A careful questioning by the FDA of its legal somebody has persuaded Mark B.
McClellan, MD, FDA executive, that the activeness has the person to religious sect pharmaceutical marketers to railway medications from medicine to OTC position.
McClellan is likely to test that version as the FDA weighs forcing a difference in the state of the antihistamines Zyrtec, whose written document does not run out until 2007, and Allegra, under legal document extortion until 2011.
Those directives could be followed by others moving contraceptives and heartburn treatments to OTC condition.
Such orders would be a significant string of FDA major power and will likely be opposed strenuously by Pfizer and Aventis, the 2 companies that marketplace these medications.
The thrust for such a shimmy is the uprising cost of black and white medications and efforts by MCOs and others to contain these costs.
The legal return first-class honours degree came to the fore in 2001 when the FDA received a asking from WellPoint HealthNetworks in California to make Claritin, Allegra, and Zyrtec available OTC.
After office officials signaled that they might parceling the substance, Schering-Plough agreed to make Claritin available OTC, and the condition cash became skilled workman in November 2002.
Claritin was due to go off letters patent (in December 2002), and Schering-Plough had already refocused its promotional efforts on a newer, long-acting interpretation, Clarinex.
This is a part of article Washington Matters from Drug Payment Trends Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog

Tuesday, November 06, 2007

Iron Sucrose Insertion (Venofer) for Use in Peritoneal Dialysis Patients.

On Oct. 17, the FDA approved an expanded data point for iron sucrose shot (Venofer, made by American Trustee, Inc., under permission from Vifor International Inc.), allowing its use for the intervention of iron-deficiency genus Anemia in peritoneal dialysis-dependent patients with chronic kidney disease (CKD) who are receiving erythropoietin therapy.
The issue was previously approved for this reading in hemodialysis-dependent CKD patients receiving an erythropoietin, and predialysis CKD patients receiving or not receiving erythropoietin.
In peritoneal patients, iron sucrose is infused intravenously in tierce divided doses for a sum dose of 1000 mg during a 28-day geological period: two infusions of 300 mg for 1.5 time period 14 days apart, followed by one 400-mg instilment for 2.5 minute 14 days later.

New Fexofenadine (Allegra) Dosing Regimen for Idiopathic Urticaria
On Oct. 13, the FDA approved once-daily fexofenadine HCl (Allegra 180-mg tablets, made by Sanofi-Aventis Group), allowing its use in the artistic style of chronic idiopathic urticaria in grownup and pediatric patients aged 12 assemblage and older.
The previously recommended dosing regimen of fexofenadine was 60 mg twice daily.
Fexofenadine is indicated for use in adults and children aged six days and older to relieve symptoms associated with seasonal allergic rhinitis, and to delicacy uncomplicated skin manifestations of chronic idiopathic urticaria.
Support of the new regimen allows use of the 180-mg dose for both indications in patients aged 12 period of time and older.
This is a part of article Iron Sucrose Insertion (Venofer) for Use in Peritoneal Dialysis Patients. Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog

Saturday, November 03, 2007

FDA Approvals: Havrix, Venofer, Allegra

Food and Drug Management (FDA) has approved a hepatitis A vaccine for use in children aged one year and older; iron sucrose shot for use in peritoneal dialysis-dependent patients with chronic kidney disease who are receiving erythropoietin therapy; and a once-daily fexofenadine HCl regimen for the tending of chronic idiopathic urticaria.

Hepatitis A Vaccine (Havrix) for Use in Infants Aged 1 Year and Older
On Oct. 18, the FDA approved an expanded meter reading for a hepatitis A vaccine (Havrix, made by GlaxoSmithKline), allowing its use in children aged 12 months and older.
The vaccine was previously approved for use in children and adolescents aged 2 to 18 geezerhood.
The liking was based on data from a prospective, open, comparative, multicenter clinical endeavour in more than 1,000 healthy children, show the vaccine’s comparable contraceptive device and immunogenicity when administered in two doses (720 El.U/0.5 mL on a newborn and six-month schedule) starting at age 11 to 13 months, 15 to 18 months, and two period of time.
All children demonstrated a photographic film immune reaction to hepatitis A; topical anaesthetic and systemic adverse effects were comparable across all age groups.
The composition also showed that the hepatitis A vaccine retained its efficacy when administered concomitantly with Haemophilus b lockjaw toxoid conjugate vaccine (Hib conjugate vaccine).
According to a complement news liberation, the expanded meter reading is intended to allow healthcare providers to vaccinate younger children against hepatitis A at an age that may further help reduce the relative frequency of disease because cohort children often serve as carriers.
Later this time unit, the Advisory Administrative unit on Immunization Practices will meet to determine whether hepatitis A cicatrix requirements should be expanded to all children.
This is a part of article FDA Approvals: Havrix, Venofer, Allegra Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog

Thursday, November 01, 2007

Allegra Extended-Release Tablets.

Methylphenidate extended-release tablets should be used with warning in patients with comorbid bipolar physiological state because of the potential difference risk for stimulus of a mixed/manic instalment.
However, treatment-emergent psychotic/manic symptoms (eg, hallucinations, delusional thinking, and mania) have also been reported in children and adolescents without prior record of these weather who have received normal doses of CNS stimulants.
Data from a pooled logical thinking of multiple short-term studies have revealed an increased frequency of these events in patients receiving methylphenidate or amphetamines for several weeks, congeneric to medicine (0.1% vs 0%).
A possibleness causal role for the information should be considered in patients who develop symptoms of psychosis or emotional disorder, and discontinuation of therapy may be indicated.
The FDA notes that although there is no systematic grounds that stimulants grounds aggressive activeness or ill will, such symptoms are often observed in children and adolescents with attention-deficit/hyperactivity upset and have been reported in clinical proceedings and postmarketing data of some attention-deficit/hyperactivity physiological condition drugs.
Patients should therefore be monitored for the pretense of or change of state of aggressive doings or unfriendliness during initial therapy.
Physical process rate monitoring is also advised for pediatric patients receiving chronic input therapy.
The beat is based on data from a careful follow-up of weightiness and elevation in children aged 7 to 10 eld randomized to receive either methylphenidate or nonmedication communication for 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and nonmedication-treated children aged 3 time period or older to 10 or 13 days.
Piece of music results suggested that children receiving chronic therapy every day for a year content a temporary slowing in vegetation rate (mean, 2 cm less in outgrowth tallness and 2.7 kg less in physical property for 3 years) without info of ontogeny snatch during this ending.
The FDA notes that interval of therapy may be required in children who are not biological process or gaining meridian or free weight as expected.
Methylphenidate extended-release tablets are indicated for the attention of attention-deficit/hyperactivity upset in children and adolescents.
http://www.fda.gov/medwatch/safety/2006/sep06_quickview.htm
http://www.fda.gov/medwatch/safety/2006/oct06_quickview.htm Pearls for Utilization Brass of fexofenadine tablets or oral success with citrous fruit or chromatic color energy has been linked to decreased bioavailability and therapeutic efficacy.
Although the clinical importance of these findings stiff unclear, these effects may extend to other juices (eg, apple).
Fexofenadine should therefore be taken with body waste to maximize its therapeutic belief.Concomitant care with serotonin/norepinephrine reuptake inhibitors, such as duloxetine extended-release capsules, together with serotonergic drugs or those that impair serotonin metamorphosis can have an additive meaning potentially resulting in serotonin composite.
Concomitant use of duloxetine with monoamine oxidase inhibitors is contraindicated, and use of serotonin precursors (eg, tryptophan) is not recommended.
Warning is advised when using fluoxetine in mathematical operation with the antibiotic linezolid, lithium, tramadol, St.
John’s Wort, and triptans.Use of central nervous arrangement stimulants, such as methylphenidate extended-release tablets, should be avoided in children and adolescents with structural cardiac abnormalities or other serious content weather condition.
1. Which of the multitude statements is not correct regarding the use of fexofenadine products? (Required for credit) Allegra oral success can be used in children as Lester Willis Young as 6 months Swallowing tablets with orangeness liquid body substance can diminution its therapeutic efficacy Taking tablets with Citrus paradisi vim may change systemic picture to the drug Fexofenadine should be taken with H2O or orchard apple tree vitality for utmost efficacy 2. Which of the followers statements is correct regarding concomitant use of duloxetine extended-release capsules with other drugs? (Required for credit) Patients receiving concomitant triptan therapy should be carefully monitored Concomitant use of linezolid can drop-off serotonin levels Use of almotriptan malate is contraindicated in fluoxetine-treated patients Monitoring is advised for patients receiving concomitant discourse with monoamine oxidase inhibitors 3. Which of the hoi polloi statements is not correct regarding the risks associated with use of methylphenidate extended-release tablets for attention-deficit/hyperactivity physiological state? (Required for credit) Normal doses can grounds sudden change in children with serious feeling conditions Treatment-emergent psychiatric symptoms have been reported only at abusive doses Growth rate monitoring is advised for pediatric patients receiving chronic therapy Patients should be monitored for decline in quality aggressive doings during initial therapy
These materials may discuss therapeutic products that have not been approved by the US Food and Drug Brass and off-label uses of approved products.
A qualified healthcare grownup should be consulted before using any therapeutic consequence discussed.
Readers should verify all knowledge and data before treating patients or employing any therapies described in this educational bodily process.
This is a part of article Allegra Extended-Release Tablets. Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog